Literature DB >> 27599521

Non-alcoholic fatty liver disease and progression of coronary artery calcium score: a retrospective cohort study.

Dong Hyun Sinn1, Danbee Kang2, Yoosoo Chang3,4,5, Seungho Ryu3,4,5, Seonhye Gu6, Hyunkyoung Kim6, Donghyeong Seong2, Soo Jin Cho7, Byoung-Kee Yi2,8, Hyung-Doo Park9, Seung Woon Paik1, Young Bin Song1,10, Mariana Lazo10, Joao A C Lima10, Eliseo Guallar10, Juhee Cho2,3,5,10, Geum-Youn Gwak1.   

Abstract

BACKGROUND AND AIM: Non-alcoholic fatty liver disease (NAFLD), a hepatic manifestation of the metabolic syndrome, was associated with subclinical atherosclerosis in many cross-sectional studies, but the prospective association between NAFLD and the progression of atherosclerosis has not been evaluated. This study was conducted to evaluate the association between NAFLD and the progression of coronary atherosclerosis.
METHODS: This retrospective cohort study included 4731 adult men and women with no history of cardiovascular disease (CVD), liver disease or cancer at baseline who participated in a repeated regular health screening examination between 2004 and 2013. Fatty liver was diagnosed by ultrasound based on standard criteria, including parenchymal brightness, liver-to-kidney contrast, deep beam attenuation and bright vessel walls. Progression of coronary artery calcium (CAC) scores was measured using multidetector CT scanners.
RESULTS: The average duration of follow-up was 3.9 years. During follow-up, the annual rate of CAC progression in participants with and without NAFLD were 22% (95% CI 20% to 23%) and 17% (16% to 18%), respectively (p<0.001). The multivariable ratio of progression rates comparing participants with NAFLD with those without NAFLD was 1.04 (1.02 to 1.05; p<0.001). The association between NAFLD and CAC progression was similar in most subgroups analysed, including in participants with CAC 0 and in those with CAC >0 at baseline.
CONCLUSIONS: In this large cohort study of adult men and women with no history of CVD, NAFLD was significantly associated with the development of CAC independent of cardiovascular and metabolic risk factors. NAFLD may play a pathophysiological role in atherosclerosis development and may be useful to identify subjects with a higher risk of subclinical disease progression. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  CARDIOVASCULAR DISEASE; FATTY LIVER; FIBROSIS; ULTRASONOGRAPHY

Mesh:

Substances:

Year:  2016        PMID: 27599521     DOI: 10.1136/gutjnl-2016-311854

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  41 in total

Review 1.  Non-alcoholic fatty liver disease.

Authors:  James Maurice; Pinelopi Manousou
Journal:  Clin Med (Lond)       Date:  2018-06       Impact factor: 2.659

Review 2.  Addressing Knowledge Gaps in the 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: a Review of Recent Coronary Artery Calcium Literature.

Authors:  Vasanth Sathiyakumar; Roger S Blumenthal; Khurram Nasir; Seth S Martin
Journal:  Curr Atheroscler Rep       Date:  2017-02       Impact factor: 5.113

3.  Association between nonalcoholic fatty liver disease with advanced fibrosis and stroke.

Authors:  Neal S Parikh; Lisa B VanWagner; Mitchell S V Elkind; Jose Gutierrez
Journal:  J Neurol Sci       Date:  2019-10-13       Impact factor: 3.181

4.  Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis.

Authors:  Robert M Wilechansky; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Emelia J Benjamin; Michelle T Long
Journal:  Liver Int       Date:  2019-05-24       Impact factor: 5.828

Review 5.  Pathogenesis of non-alcoholic fatty liver disease and implications on cardiovascular outcomes in liver transplantation.

Authors:  Benedict J Maliakkal
Journal:  Transl Gastroenterol Hepatol       Date:  2020-07-05

6.  Liver Fat Is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study.

Authors:  Zachary P Fricker; Alison Pedley; Joseph M Massaro; Ramachandran S Vasan; Udo Hoffmann; Emelia J Benjamin; Michelle T Long
Journal:  Clin Gastroenterol Hepatol       Date:  2018-11-23       Impact factor: 11.382

7.  The Association of Alanine Aminotransferase Levels With Myocardial Perfusion Imaging and Cardiovascular Morbidity.

Authors:  David Yardeni; Ronen Toledano; Victor Novack; Aryeh Shalev; Arik Wolak; Yaron Rotman; Ohad Etzion
Journal:  J Cardiovasc Pharmacol Ther       Date:  2022 Jan-Dec       Impact factor: 2.457

8.  Association between PNPLA3 rs738409 G variant and MRI cerebrovascular disease biomarkers.

Authors:  Neal S Parikh; Nicole Dueker; Dalila Varela; Victor J Del Brutto; Tatjana Rundek; Clinton B Wright; Ralph L Sacco; Mitchell S V Elkind; Jose Gutierrez
Journal:  J Neurol Sci       Date:  2020-06-20       Impact factor: 3.181

9.  Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.

Authors:  Jung Gil Park; Jinho Jung; Kritin K Verma; Min Kyu Kang; Egbert Madamba; Scarlett Lopez; Aed Qas Yonan; Amy Liu; Ricki Bettencourt; Claude Sirlin; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2021-03-25       Impact factor: 8.171

10.  A radioiodinated FR-β-targeted tracer with improved pharmacokinetics through modification with an albumin binder for imaging of macrophages in AS and NAFL.

Authors:  Xuejun Wen; Changrong Shi; Liu Yang; Xinying Zeng; Xiaoru Lin; Jinxiong Huang; Yesen Li; Rongqiang Zhuang; Haibo Zhu; Zhide Guo; Xianzhong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-21       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.